肥胖与精神药物。
Obesity and psychotropics.
机构信息
SUNY Upstate Medical University, NY, USA.
出版信息
CNS Neurosci Ther. 2012 Jan;18(1):57-63. doi: 10.1111/j.1755-5949.2011.00232.x. Epub 2011 May 9.
Abstract
Weight gain is on the rise in the United States as is the diagnosis and treatment of mental disorders. These two phenomena are distinctly separate but tend to overlap in that most psychotropic agents approved for use in the United States are associated with the potential to induce weight gain. Metabolic disorders such as diabetes, hypercholesterolemia, and hypertension are also on the rise and often associated with weight gain and clearly associated with certain psychotropic medications. This article serves to provide a succinct review regarding the epidemiology, etiology, and treatment options for psychotropic-induced obesity.
摘要
在美国，体重增加的现象正在上升，同时精神障碍的诊断和治疗也在增加。这两种现象是明显分开的，但往往会重叠，因为大多数在美国被批准使用的精神药物都有可能导致体重增加。代谢紊乱，如糖尿病、高胆固醇血症和高血压也在上升，通常与体重增加有关，并且与某些精神药物明显相关。本文旨在提供关于精神药物引起的肥胖的流行病学、病因和治疗选择的简明综述。
相似文献
1
Obesity and psychotropics.肥胖与精神药物。
CNS Neurosci Ther. 2012 Jan;18(1):57-63. doi: 10.1111/j.1755-5949.2011.00232.x. Epub 2011 May 9.
2
[Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].[精神药物所致体重增加：关于流行病学数据、机制及管理的文献综述]
Encephale. 2005 Jul-Aug;31(4 Pt 1):507-16. doi: 10.1016/s0013-7006(05)82412-1.
3
Psychiatric medication-induced obesity: a review.精神科药物所致肥胖：综述
Obes Rev. 2004 May;5(2):115-21. doi: 10.1111/j.1467-789X.2004.00139.x.
4
Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population.精神药物引起的体重增加和其他代谢并发症在瑞士精神科人群中的表现。
J Psychiatr Res. 2012 Apr;46(4):540-8. doi: 10.1016/j.jpsychires.2012.01.014. Epub 2012 Feb 7.
5
Pharmacotherapy for psychotropic drug-related weight gain.用于治疗精神药物所致体重增加的药物治疗
J Psychosoc Nurs Ment Health Serv. 2008 Jul;46(7):15-8. doi: 10.3928/02793695-20080701-06.
6
Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.精神药物的不良内分泌和代谢效应：选择性临床述评。
CNS Drugs. 2009 Dec;23(12):1003-21. doi: 10.2165/11530020-000000000-00000.
7
The Other Obesity Epidemic-Of Drugs and Bugs.另一种肥胖症流行——药物和细菌。
Front Endocrinol (Lausanne). 2020 Jul 31;11:488. doi: 10.3389/fendo.2020.00488. eCollection 2020.
8
Psychotropic drug considerations in depressed patients with metabolic disturbances.伴有代谢紊乱的抑郁症患者的精神药物考量
Am J Med. 2008 Aug;121(8):647-55. doi: 10.1016/j.amjmed.2007.08.043.
9
'Why getting fat, Doc?' Weight gain and psychotropic medications.“医生，为什么我会发胖？”体重增加与精神类药物
Aust N Z J Psychiatry. 2001 Jun;35(3):315-21. doi: 10.1046/j.1440-1614.2001.00891.x.
10
Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.精神病患者药物性体重增加的流行病学、影响及潜在机制。
J Psychiatr Res. 2003 May-Jun;37(3):193-220. doi: 10.1016/s0022-3956(03)00018-9.
引用本文的文献
1
Obesity-associated factors in psychiatric outpatients: A multicenter questionnaire survey.精神科门诊患者肥胖相关因素的多中心问卷调查。
Neuropsychopharmacol Rep. 2024 Sep;44(3):620-630. doi: 10.1002/npr2.12465. Epub 2024 Jul 15.
2
Severe Maternal Morbidity and Maternal Mortality in Women With Intellectual and Developmental Disabilities.智力和发育障碍妇女的严重产妇发病率和产妇死亡率。
Am J Prev Med. 2021 Dec;61(6):872-881. doi: 10.1016/j.amepre.2021.05.041. Epub 2021 Sep 25.
3
Can treatment of obesity reduce depression or vice versa?治疗肥胖症能否减轻抑郁，反之亦然？
J Psychiatry Neurosci. 2021 Apr 20;46(2):E313-E318. doi: 10.1503/jpn.210036.
4
Weight outcomes in children with developmental disabilities from a multidisciplinary clinic.多学科诊所中发育障碍儿童的体重结果
Res Dev Disabil. 2021 Jan;108:103809. doi: 10.1016/j.ridd.2020.103809. Epub 2020 Nov 18.
5
Prevalence and Associated Factors of Metabolic Syndrome among Patients with Severe Mental Illness Attending a Tertiary Hospital in Southwest Uganda.乌干达西南部一家三级医院严重精神疾病患者代谢综合征的患病率及其相关因素。
Biomed Res Int. 2019 Nov 11;2019:1096201. doi: 10.1155/2019/1096201. eCollection 2019.
6
Weight changes associated with antiepileptic mood stabilizers in the treatment of bipolar disorder.抗癫痫心境稳定剂治疗双相情感障碍时的体重变化
Eur J Clin Pharmacol. 2018 Nov;74(11):1485-1489. doi: 10.1007/s00228-018-2517-2. Epub 2018 Aug 7.
7
Mental Illness and Psychotropic Medication use Among People Assessed for Bariatric Surgery in Ontario, Canada.加拿大安大略省接受减肥手术评估人群中的精神疾病与精神药物使用情况
Obes Surg. 2016 Jul;26(7):1531-6. doi: 10.1007/s11695-015-1905-2.
8
From simplicity towards complexity: the Italian multidimensional approach to obesity.从简单到复杂：意大利对肥胖症的多维研究方法。
Eat Weight Disord. 2014;19(3):387-94. doi: 10.1007/s40519-013-0097-9. Epub 2014 Jan 22.
9
Increase in neuroexcitability of unmyelinated C-type vagal ganglion neurons during initial postnatal development of visceral afferent reflex functions.未髓鞘 C 型迷走神经节神经元的神经兴奋性在内脏传入反射功能出生后早期发育过程中增加。
CNS Neurosci Ther. 2013 Dec;19(12):954-62. doi: 10.1111/cns.12195. Epub 2013 Oct 25.
本文引用的文献
1
The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia.喹硫平（思瑞康）单药治疗对精神分裂症患者体重的长期影响。
Int J Psychiatry Clin Pract. 2000;4(4):287-91. doi: 10.1080/13651500050517849.
2
Management of antipsychotic-related weight gain.抗精神病药相关体重增加的管理。
Expert Rev Neurother. 2010 Jul;10(7):1175-200. doi: 10.1586/ern.10.85.
3
Pharmacological management of appetite expression in obesity.肥胖症中食欲表达的药物治疗管理。
Nat Rev Endocrinol. 2010 May;6(5):255-69. doi: 10.1038/nrendo.2010.19. Epub 2010 Mar 16.
4
Aripiprazole in schizophrenia and schizoaffective disorder: A review.阿立哌唑治疗精神分裂症和分裂情感性障碍：综述。
Clin Ther. 2010;32 Suppl 1:S3-20. doi: 10.1016/j.clinthera.2010.01.021.
5
Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.阿塞那平治疗双相 I 型障碍急性躁狂：一项随机、双盲、安慰剂对照试验。
J Affect Disord. 2010 Apr;122(1-2):27-38. doi: 10.1016/j.jad.2009.12.028. Epub 2010 Jan 22.
6
Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.在一项多中心试验中，普兰林肽与西布曲明或 phentermine 联合使用可增强减肥效果。
Obesity (Silver Spring). 2010 Sep;18(9):1739-46. doi: 10.1038/oby.2009.478. Epub 2010 Jan 21.
7
Zonisamide Combined with Cognitive Behavioral Therapy in Binge Eating Disorder: A One-year Follow-up Study.唑尼沙胺联合认知行为疗法治疗暴饮暴食症：一项为期一年的随访研究。
Psychiatry (Edgmont). 2009 Nov;6(11):23-8.
8
Drugs in the pipeline for the obesity market.肥胖症市场正在研发中的药物。
J Diabetes Sci Technol. 2008 Sep;2(5):913-8. doi: 10.1177/193229680800200525.
9
Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder.阿塞那平单药治疗精神分裂症和双相 I 障碍的急性期。
Neuropsychiatr Dis Treat. 2009;5:483-90. doi: 10.2147/ndt.s5742. Epub 2009 Oct 12.
10
Asenapine versus olanzapine in acute mania: a double-blind extension study.阿塞那平与奥氮平治疗急性躁狂：一项双盲扩展研究。
Bipolar Disord. 2009 Dec;11(8):815-26. doi: 10.1111/j.1399-5618.2009.00749.x. Epub 2009 Oct 14.
Zotero 插件